OR WAIT null SECS
Adamis Pharmaceuticals agrees to license and potentially acquire 3M's Taper Dry Powder Inhaler technology.
The biopharmaceutical company Adamis Pharmaceuticals has formalized an agreement with 3M to exclusively license and, with additional payment, fully acquire 3M's Taper Dry Powder Inhaler (DPI) technology under development for the treatment of asthma and chronic obstructive pulmonary disease. As a part of the agreement, Adamis will obtain worldwide rights to use this platform technology in all indications in the dry-powder inhalation field. The design uses proprietary 3M technology to store API on a microstructured carrier tape. 3M will supply the drug-delivery tape for the platform to Adamis under a separate supply agreement.
Under the terms of the agreement, Adamis made an initial payment to exclusively license the Taper technology through Dec. 31, 2013, and upon payment of an additional amount before Dec. 31, 2013, will fully acquire the Taper technology.
Source: Adamis Pharmaceuticals